BSR_09_0163_C1_S96
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MYC_TARGETS_V2+0.480
- G2M_CHECKPOINT+0.460
- INTERFERON_ALPHA_RESPONSE+0.460
- INTERFERON_GAMMA_RESPONSE+0.400
- MYC_TARGETS_V1+0.370
- MTORC1_SIGNALING+0.330
- DNA_REPAIR+0.230
- GLYCOLYSIS+0.230
- PI3K_AKT_MTOR_SIGNALING+0.190
Top 10 suppressed
- UV_RESPONSE_DN-0.340
- ESTROGEN_RESPONSE_EARLY-0.260
- MYOGENESIS-0.260
- BILE_ACID_METABOLISM-0.220
- HEME_METABOLISM-0.220
- NOTCH_SIGNALING-0.220
- PEROXISOME-0.190
- APICAL_JUNCTION-0.160
- ESTROGEN_RESPONSE_LATE-0.160
- FATTY_ACID_METABOLISM-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168607 | — | — | 0.870 |
| 2 | SRR8518360 | — | E | 0.825 |
| 3 | TCGA-A2-A0D0-01A-11R-A00Z-07 | — | E | 0.824 |
| 4 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.816 |
| 5 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.815 |
| 6 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.807 |
| 7 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.806 |
| 8 | SRR12475159 | — | — | 0.806 |
| 9 | TCGA-NC-A5HM-01A-12R-A26W-07 | — | cohortSQ1 | 0.804 |
| 10 | SRR8518265 | — | E | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |